Review of U.S. registries for psoriasis
Authors:
- 2 October 2017
- journal article
- review article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 28 (8) , 697-701
Abstract
Background: Patient registries are databases comprised of standardized clinical data for a specific population of patients with a particular disease or medical condition. Information from patient registries allows clinicians to assess long-lasting outcomes in patients with a specific disease, such as psoriasis. Objective: Our primary objective was to identify available psoriasis registries in the United States (U.S.) and evaluate the application of patient registries compared to clinical trials. Methods: We searched Google, the Registry of Patient Registries, Orphanet and ClinicalTrials.gov to create a list of U.S. psoriasis registries. We also performed a literature review on the application of psoriasis registries using PubMed. Results: We identified 6 psoriasis patient registries in the United States. Conclusions: Patient registries are frequently used for psoriasis in the U.S. and provide important information about the safety, efficacy and long-term effects of systemic therapies.Keywords
Funding Information
- AbbVie
- Instituto de Salud Carlos III
- ISCIII
- Amgen
- AstraZeneca
- Boehringer Ingelheim
- Coherus Biosciences
- Dermira
- Eli Lilly
- Janssen
- Merck
- Novartis
- Pfizer
- Regeneron
- Sandoz
- Sun Pharmaceutical Industries
This publication has 15 references indexed in Scilit:
- Review of patient registries in dermatologyJournal of the American Academy of Dermatology, 2016
- Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Journal of the American Academy of Dermatology, 2016
- Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Journal of the European Academy of Dermatology and Venereology, 2016
- Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasisJournal of the American Academy of Dermatology, 2015
- Risk of Serious Infection With Biologic and Systemic Treatment of PsoriasisJAMA Dermatology, 2015
- OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year resultsJournal of the American Academy of Dermatology, 2015
- Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease‐based registry (PSOLAR)British Journal of Dermatology, 2014
- OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasisJournal of the American Academy of Dermatology, 2013
- Significance of Patient Registries for Dermatological DisordersJournal of Investigative Dermatology, 2012
- Psoriasis Therapy in Real Life: The Need for RegistriesDermatology, 2006